Eligo Bioscience secures grant to advance topical gene delivery platform
Biotechnology company Eligo Bioscience has obtained a $5m grant from the French Government to expedite the development and upscaling of…
Dermatology
-
-
Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA)…
-
Alumis and Kaken sign agreement in Japan to develop ESK-001
Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and commercialisation of the former’s…
-
Menarini to enhance BPDCN detection with VisualDx’s link
The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the detection of…
-
Galderma enters fierce European atopic dermatitis market with Nemluvio approval
Galderma has won approval from the European Commission (EC) for subcutaneous injection Nemluvio (nemolizumab) for the treatment of atopic dermatitis…
-
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4…
-
FDA approves Galderma’s Nemluvio to treat atopic dermatitis
The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and…
-
AbbVie to acquire Nimble Therapeutics for $200m
AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim…
-
LEO Pharma’s eczema cream gains MHRA marketing authorisation
LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus…
-
J&J’s sBLAs seek FDA approval of TREMFYA for paediatric conditions
Johnson & Johnson (J&J) has sought approval for TREMFYA (guselkumab) for paediatric conditions with the submission of two supplemental biologics licence…
